Psychometric properties of a lipodystrophy scale

AIDS Patient Care and STDs

Volumn 20, Issue 1, 2006, Pages 30-35

  Lee, Daniel ^a,d   Patel, Parul ^b   Sachs, Jennifer ^a   Basinger, Susan ^c   Mathews, W Christopher ^a   Barber, R Edward ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMD SERONO INC   (United States)

^d UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BISEXUALITY; BODY MASS; CD4 LYMPHOCYTE COUNT; DEMOGRAPHY; DISEASE SEVERITY; ETHNOLOGY; FACTORIAL ANALYSIS; FEMALE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HOMOSEXUALITY; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PSYCHOMETRY; RELIABILITY; SEX RATIO; UNIVERSITY HOSPITAL; VIRUS LOAD;

ADULT; AGED; AMBULATORY CARE FACILITIES; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; PHYSICAL EXAMINATION; PSYCHOMETRICS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 31644443760     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.20.30     Document Type: Article

References (31)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-58.
2. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;351:871-875.
3. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35-43.
4. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999;100:700-705.
5. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351:867-870.
6. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing anti-retroviral therapy: Preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
7. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-1316.
8. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 1998;27:65-67.
9. John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001;6:9-20.
10. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999,20:228-237.
11. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003;17:971-979.
12. Tien PC, Grunfeld C. What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis 2004;17:27-32.
13. Tien PC, Cole SR, Williams CM, et al. Incidence of lipoatrophy and lipohypertrophy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2003;34:461-466.
14. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 2003;361:726-735.
15. Oversight Committee for the Evaluation of the Metabolic Complications of HAART. The evaluation of metabolic function and fat redistribution in clinical trials. HIV Medicine 2002;3:65-72.
16. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001;15:F11-18.
17. Grunfeld C. Preliminary data on men from the study of fat redistribution and metabolic change in HIV infection (FRAM). Oral Presentation from the XIV International AIDS Conference [Oral Presentation TuOr158]. Barcelona, Spain: July 7-12, 2002.
18. Toma E, Devost D, Chow Lan N, Bhat PV. HIV-protease inhibitors alter retinoic acid synthesis. AIDS 2001;15:1979-1984.
19. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-1883.
20. Lenhard JM, Weiel JE, Paulik MA, Furfine ES. Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir. Biochem Pharmacol 2000;59:1063-1068.
21. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389-1398.
22. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: Results of a substudy from a comparative trial. AIDS 2002;16:2447-2454.
23. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003;32:48-56.
24. Gripshover B, Tien PC, Saag M, et al. Lipoatrophy is the Dominant Feature of the Lipodystrophy Syndrome in HIV-Infected Men [Abstract 732]. Abstracts from the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA: February 10-14, 2003.
25. Smit E, Semba RD, Pilibosian E, et al. Body habitus in a cohort of HIV-seropositive and HIV-seronegative injection drug users. AIDS Patient Care STDS 2005;19:19-30.
26. Oette M, Juretzko P, Kroidl A, et al. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care STDs 2002;16:413-417.
27. Schwenk A, Breuer P, Kremer G, Ward L. Clinical assessment of HIV-associated lipodystrophy syndrome: Bioelectrical impedance analysis, anthropometry and clinical scores. Clin Nutr 2001;20:243-249.
28. Wanke C, Polsky B, Kotler D. Guidelines for using body composition measurement in patients with human immunodeficiency virus infection. AIDS Patient Care STDs 2002;16:375-388.
29. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334.
30. Afifi A, Clark VA, May S. Computer-Aided Multivariate Analysis, 4th ed. New York: Chapman and Hall/CRC, 2004:391-416.
31. Byrt T. How good is that agreement? Epidemiology 1996;7:561.